Prelude Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Prelude Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-4,000	Closed	-$1.16M	–	2395
2020 Q2	$1.16M	Buy	+4,000	New	+$1.08M	0.06%	276
2017 Q1	–	Sell	-9,400	Closed	-$692K	–	1799
2016 Q4	$692K	Buy	+9,400	New	+$765K	0.08%	261
2014 Q3	–	Sell	-100	Closed	-$9K	–	2155
2014 Q2	$9K	Sell	100 -1,000	-91%	-$70.1K	﹤0.01%	1825
2014 Q1	$78K	Sell	1,100 -500	-31%	-$39.6K	0.01%	1127
2013 Q4	$119K	Buy	+1,600	New	+$111K	0.02%	800

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Prelude Capital Management's VRTX Position: Q1 2026 in Review

Prelude Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 463 shares — an estimated $210K sold.

Prelude Capital Management first reported a position in VRTX in Q2 2013 and held it in 40 quarters. The position peaked at $5.43M in Q2 2018. 1,688 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Prelude Capital Management reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Prelude Capital Management sold 463 Vertex Pharmaceuticals shares in Q1 2026, an estimated $210K.
Prelude Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 40 quarters.
Prelude Capital Management's Vertex Pharmaceuticals position peaked at $5.43M in Q2 2018.
1,688 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.